Transgene Loses Roche As A Partner But Stays The Course On Strategy
This article was originally published in The Pink Sheet Daily
Roche backed out of a development deal with Transgene for a therapeutic vaccine, but the French drug developer says the implications, at least for the short term, are minimal.
You may also be interested in...
No longer the odd cousins of traditional pharmaceutical applications, a host of therapeutic cancer vaccines is working through late-stage trials with real, life-extending data already reported and the potential to create a lot of action in the oncology sector.
Transgene to raise more capital following the granting of an exclusive option on its lead product to Novartis.
Deal has “potential to expand and evolve into an integrated personalized medicine approach” to HPV-mediated diseases, Roche tells “The Pink Sheet” DAILY.